Risk Factors for Endometrial Lesions Detected by Hysteroscopy in Breast Cancer Patients Taking Tamoxifen
1. First Clinical Medical College, Nanjing Medical University, Nanjing 210036, China 2. Department of Gynecology, the First Affiliated Hospital with Nanjing Medical University, Nanjing 210036, China
LI Yujing,JIN Yichao,CHEN Xing, et al. Risk Factors for Endometrial Lesions Detected by Hysteroscopy in Breast Cancer Patients Taking Tamoxifen[J]. Chinese General Practice, 2023, 26(32): 4026-4030. DOI: 10.12114/j.issn.1007-9572.2023.0161.
李雨荆,晋一超,陈醒等. 服用他莫昔芬的乳腺癌患者宫腔镜检出子宫内膜病变的危险因素研究[J]. 中国全科医学, 2023, 26(32): 4026-4030. DOI: 10.12114/j.issn.1007-9572.2023.0161.
Table 1 Comparison of clinical data between the two groups of patients
组别
例数
年龄〔M(P25,P75),岁〕
BMI(kg/m2)
高血压史〔例(%)〕
糖尿病史〔例(%)〕
分娩次数〔M(P25,P75),次〕
绝经〔例(%)〕
AUB/PMB〔例(%)〕
化疗〔例(%)〕
宫腔镜内膜活检阴性组
43
52(46,54)
23.6±3.4
6(14.0)
0
1(0,3)
29(67.4)
3(7.0)
24(55.8)
宫腔镜内膜活检阳性组
89
49(44,52)
23.2±2.5
18(20.2)
5(5.6)
1(1,1)
49(55.1)
25(28.1)
63(70.8)
检验统计量值
-1.046a
0.529b
0.766
1.206c
-1.940a
1.840
7.733
2.893
P值
0.296
0.598
0.381
0.272
0.052
0.175
0.005
0.089
组别
GnRH-a〔例(%)〕
TAM用药时间〔例(%)〕
子宫内膜厚度(mm)
宫腔内高回声占位〔例(%)〕
宫腔内无回声占位〔例(%)〕
宫腔内异常血流信号〔例(%)〕
≥24个月
<24个月
宫腔镜内膜活检阴性组
4(9.3)
20(46.5)
23(53.5)
9.49±3.79
2(4.8)
15(35.7)
1(2.4)
宫腔镜内膜活检阳性组
9(10.1)
58(65.2)
31(34.8)
12.44±4.66
30(33.7)
31(34.8)
10(11.2)
检验统计量值
0.021
4.175
-3.566b
11.430
0.010
1.871
P值
0.884
0.041
0.001
<0.001
0.921
0.171
Table 2 Multivariate Logistic regression analysis of the influencing factors for endometrial lesions detected by hysteroscopy in breast cancer patients taking TAM
Table 2 Multivariate Logistic regression analysis of the influencing factors for endometrial lesions detected by hysteroscopy in breast cancer patients taking TAM
自变量
β
SE
Wald χ2值
P值
OR值
95%CI
AUB/PMB
2.045
0.703
8.462
0.004
7.731
(1.949,30.699)
TAM用药时间≥24个月
0.384
0.450
0.728
0.394
1.468
(0.608,3.549)
子宫内膜厚度
0.201
0.058
11.990
0.001
1.223
(1.091,1.371)
宫腔内高回声占位
2.594
0.807
10.328
0.001
13.383
(2.751,65.103)
Figure 1 ROC curve of endometrial thickness for predicting endometrial lesions detected by hysteroscopy in breast cancer patients taking TAM
Figure 1 ROC curve of endometrial thickness for predicting endometrial lesions detected by hysteroscopy in breast cancer patients taking TAM
RYUK J,KIMM S,LEEJ Y,et al. Risk of endometrial polyps,hyperplasia,carcinoma,and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer[J]. JAMA Netw Open,2022,5(11):e2243951. DOI:10.1001/jamanetworkopen.2022.43951.
[3]
BERCEANUC,CERNEAN,CAPITANESCUR G,et al. Endometrial polyps[J]. Rom J Morphol Embryol,2022,63(2):323-334. DOI:10.47162/RJME.63.2.04.
[4]
LEEM,PIAOJ L,JEONM J. Risk factors associated with endometrial pathology in premenopausal breast cancer patients treated with tamoxifen[J]. Yonsei Med J,2020,61(4):317. DOI:10.3349/ymj.2020.61.4.317.
[5]
SARIOGLUE,VURALF,DENIZ ERTÜRK COS’KUNA. The relationship of endometrial pathologies with endometrial thickness and inflammatory markers in breast cancers using tamoxifen[J].Arch Gynecol Obstet,2023,307(2):565-571. DOI:10.1007/s00404-022-06608-y.
[6]
JEONJ,KIMS E,LEED Y,et al. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer:a retrospective analysis of 821 biopsies[J]. Breast Cancer Res Treat,2020,179(1):125-130. DOI:10.1007/s10549-019-05448-w.
GRADISHARW J,MORANM S,ABRAHAMJ,et al. Breast cancer,version 3.2022,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2022,20(6):691-722. DOI:10.6004/jnccn.2022.0030.
[9]
SASAKIL M P,ANDRADEK R C,FIGUEIREDOA C M G,et al. Factors associated with malignancy in hysteroscopically resected endometrial polyps:a systematic review and meta-analysis[J]. J Minim Invasive Gynecol,2018,25(5):777-785. DOI:10.1016/j.jmig.2018.02.004.
[10]
KEDARR P,BOURNET H,POWLEST J,et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial[J]. Lancet,1994,343(8909):1318-1321. DOI:10.1016/s0140-6736(94)92466-x.
[11]
CHENJ Y,KUOS J,LIAWY P,et al. Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use:a population based study[J]. J Cancer,2014,5(2):151-155. DOI:10.7150/jca.8412.
[12]
BERGMANL,BEELENM L,GALLEEM P,et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen[J]. Lancet,2000,356(9233):881-887. DOI:10.1016/s0140-6736(00)02677-5.
SACCARDIC,GIZZOS,PATRELLIT S,et al. Endometrial surveillance in tamoxifen users:role,timing and accuracy of hysteroscopic investigation:observational longitudinal cohort study[J]. Endocr Relat Cancer,2013,20(4):455-462. DOI:10.1530/ERC-13-0020.
[17]
GAOW L,ZHANGL P,FENGL M. Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen[J]. Chin Med J,2011,124(15):2335-2339.
[18]
CHIOFALOB,MAZZONI,DI ANGELO ANTONIOS,et al. Hysteroscopic evaluation of endometrial changes in breast cancer women with or without hormone therapies:results from a large multicenter cohort study[J]. J Minim Invasive Gynecol,2020,27(4):832-839. DOI:10.1016/j.jmig.2019.08.007.
[19]
ABDAALA,MUSHTAQY,KHASATIL,et al. Post-menopausal bleeding - is transvaginal ultrasound a useful first-line investigation in tamoxifen users?[J]. Post Reprod Health,2018,24(2):72-78. DOI:10.1177/2053369118755190.
[20]
HEREMANSR,VAN DEN BOSCHT,VALENTINL,et al. Ultrasound features of endometrial pathology in women without abnormal uterine bleeding:results from the International Endometrial Tumor Analysis study(IETA3)[J]. Ultrasound Obstet Gynecol,2022,60(2):243-255. DOI:10.1002/uog.24910.
[21]
HULKAC A,HALLD A. Endometrial abnormalities associated with tamoxifen therapy for breast cancer:sonographic and pathologic correlation[J]. Am J Roentgenol,1993,160(4):809-812. DOI:10.2214/ajr.160.4.8456669.
[22]
YANGH,ZONGX,YUY,et al. Combined effects of goserelin and tamoxifen on estradiol level,breast density,and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer:a randomised controlled clinical trial[J]. Br J Cancer,2013,109(3):582-588. DOI:10.1038/bjc.2013.324.